nb! bringing psoriasis into the light · bringing psoriasis into the light geneva pharma forum 9...

10
Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May 2014 p. 01

Upload: others

Post on 21-Jan-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

NB! The dashed borders around

the logo graphics are not visible

in Show view or on print

Insert new picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

Insert new picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma

14 May 2014

p. 01

Page 2: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

Insert picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

Psoriasis: A chronic, non-communicable disease affecting over 125 million people worldwide

Psoriasis appears on the skin, most often as thickened, red, scaly patches that often itch and may bleed. It is a non-contagious, chronic, inflammatory disease that can be both painful and disabling.ii

More people with psoriasis need better access to the medical care and appropriate solutions for either their psoriasis or for the psychosocial issues they may face as a result of their psoriasis.ii

People with psoriasis report feeling embarrassed and helpless due to their condition.ii

14 May, 2014

p. 02

Picture: Nestle FO et al. N Engl J Med 2009;361:496-509 i "Facts about Psoriasis." Ed. Catie Coman. National Psoriasis Foundation, 2012. Web. 19 Dec. 2012. <http://www.psoriasis.org/document.doc?id=1492>. ii "Psoriasis and Mental Health Issue Brief." National Psoriasis Foundation, Jan. 2012. Web. 11 Dec. 2012 <http://www.psoriasis.org/document.doc?id=350>.

Page 3: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

People with severe psoriasis die four years younger, on average, than people without the disease. iii

As many as 30% of people with psoriasis will be diagnosed with

psoriatic arthritis, a specific form of arthritis that is painful and debilitating and causes joint damage.ii

Psoriasis increases the risk of developing diabetes,

independent of factors such as weight, hypertension and high cholesterol.iv

One study showed that psoriasis patients have a 44% increased

risk of suicidal thoughts, suicide attempts or completed suicides compared to the general population.v Another study showed that almost 10% of psoriasis patients surveyed reported a wish to be dead.vi

Burden of Disease How psoriasis affects patients

iii Gelfand JM, et al. Arch of Dermatol. 2007 Dec;143(12):1493-9. iv Neimann AL, et al. J Am Acad Dermatol. 2006;55(5):829-35. vKurd Sk, et al. Arch of Dermatol. 2010 Aug:146(8)891-5. vi Gupta MA, Gupta AK. Br J Dermatol 1998;139:846-50.

Page 4: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

To add pre-formatted

bullet text please use the

Increase/Decrease Indent

buttons found in the

Top-PowerPoint menu

Psoriasis Pipeline Projects Topicals

p. 04

14 May, 2014

Phase 1

Phase 2

Phase 3

Pre-registration

AN-2898 Anacor Pharmaceuticals

LP-001-09 LAILA

Pharmaceuticals

Pc4 Case Western Reserve

University

BYK-321084 Takeda Pharma

SHP-141 Shape

Pharmaceuticals

ENN-01 Ennar Pharrma

SOM-0606 Ennar Pharrma

BCT194 Novartis

Aganirsen Gene Signal

AN-2728 Anacor Pharmaceuticals

Apo805K1 ApoPharma

BFH-772 Novartis

CT-327 Creabilis

Cyclosporine Advancell

DPS-151 DermsPsor

E-6201 Eisai

IDP 118 Valeant

LAS-41004 Almirall

PH 10 IMCOR

Ruxolitinib Incyte Corp

Tofacitinib Pfizer Valrubicin

Valderm

Nia-114 Niadyne Pharma

Clobetasol proprionate

Foamix

AKVANO Lipidor

DLX-105 Delenex

Therapeutics AS-101 BioMas Auranofin

Viralytics

MOL4249 Moleculin

DD 25 Fortuderm

Triamcinolone acetonide

Nuvo Research

Methotrexate MediQuest

Betamethasone Valerate 0.12%

Foamix

TU-2100 Tammarking

AM-001 DermAct

Benvitimod Stiefel

Pefcalcitol Maruho

Tacrolimus Novaliq

DFD01 Promius Pharma

Ulobetasol Therapeutics

Unknown formulation Spray/Foam Microemulsion Lotion Cream Ointment Gel

4 - 6 years to market

2 - 4 years to market

1 year to market

Tazarotene + betamethasone

Chongging Huapont Pharma

*Source: Cortellis and ADIS

Page 5: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

To add pre-formatted

bullet text please use the

Increase/Decrease Indent

buttons found in the

Top-PowerPoint menu

Psoriasis Pipeline Projects Biologics

14 May 2014

p. 05

Phase 1

Phase 2

Phase 3

Pre-registration

BTT-1023 BioTie Therapies

CJM Novartis

AGM-811 Amgen

BI-655066 Boehringer Ingelheim

18C3 X-Biotech

AbGn-168 AbGenomics

Intravenous Subcutaneous Injectable

ASKP1240 Astellas Pharma

Tregalizumab AbbVie

Guselkumab Janssen Biotech

IMO-3100 Idera Pharmaceuticals

Inecalcitol Hybrigenics

IMO-8400 Idera Pharmaceuticals

4 - 6 years to market

3 - 4 years to market

1 year to market

Brodalumab Amgen Inc

Ixekizumab Eli Lilly & Co.

KHK-4827 Amgen

Tildrakizumab Schering-Plough

Corp/Merck

Secukinumab Novartis

Etanercept Biosimilar Sandoz

*Source: Cortellis and ADIS

Adalimumab Biosimilar Sandoz

Page 6: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

To add pre-formatted

bullet text please use the

Increase/Decrease Indent

buttons found in the

Top-PowerPoint menu

Psoriasis Pipeline Projects Orals

14 May 2014

p. 06

Phase 1

Phase 2

Phase 3 Pre-registration

4 - 6 years to market

2 - 4 years to market

1 year to market

*Source: Cortellis and ADIS

Otezla® (Apremilast) Celgene

CM-2489 TorreyPines/CalciMedica

CT-1578 Cell Theraputics

PRX-167700 Proximagen Group

Trichuris suis ova Coronado Biosciences

XP-23829 Xenoport Inc.

Aminopterin Syntrix Biosystems

ASP 015K Astellas Pharma

Dimethyl fumarate Forward Pharma

Baricitinib Incyte Corp/Eli Lilly Ponesimod

Actelion Ltd SRT 2104 Sirtris Pharma, a GSK company

VB-201 VBL Therapeutics

Erlotinib OSI Pharmaceuticals

CH-1504 Chelsea Therapeutics

FX-125L Boehringer Ingelheim

HBP-347 Hy BioPharma

MT-1303 Mitsubishi Tanabe Pharma

INCB-039110 Incyte Corp

LLL 3348 Lupin

CF-101 Can-Fite BioPharma

Tofacitinib Pfizer

LAS 41008 Almirall

Voclosporin Aurina Pharmaceuticals

Inecalcitol Hybrigenics

Page 7: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

To view drawing guides

1. Right-click outside slide and

select ’Grid and Guides...’

2. Check ’Display drawing

guides on screen’

3. Select ’OK’

NB! The dashed borders around

the logo graphics are not visible

in Show view or on print

Insert new picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

14 May 2014

p. 07

“A strong programmatic and multidisciplinary approach to

disease management that includes the coordination of care with

specialists and other health care professionals, as well as

consideration of patients’ needs and preferences are central to

the management of all non-communicable diseases including

psoriasis.”

- WHO Psoriasis Report, 2013

Giving patients control of their disease

Page 8: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

Insert picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

We go beyond products to offer complete care solutions

• Patient support services empowers people to take control of their skin condition

• Our care offerings aim to deliver precise and personalised information to patients – across all therapy areas

Page 9: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

Data collection What gaps do we need to fill?

14 May, 2014

p. 09

Example of interactive disease atlas

Page 10: NB! Bringing psoriasis into the light · Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma 14 May

NB! The dashed borders around

the logo graphics are not visible

in Show view or on print

Insert new picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

Insert new picture

1. Delete old picture

2. Select picture placeholder

3. Insert picture from

ImageShopper

4. Use Image Tools to pan,

crop, zoom and compress

WHO Psoriasis Resolution

14 May 2014

p. 010

The goal of getting the WHO psoriasis resolution adopted is a necessary challenge that must be met in order to create a better environment for psoriasis patients to lessen the stigma and discrimination they endure.